Trial Profile

Real World Study of Lapatinib Among Metastatic Breast Cancer Patients in Clinical Practice: a Multicenter, Retrospective Study

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 23 Jul 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lapatinib (Primary) ; Trastuzumab (Primary) ; Trastuzumab emtansine (Primary) ; Capecitabine
Indications Advanced breast cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

21 Jul 2020 Status changed from active, no longer recruiting to completed.
08 Feb 2020 Planned End Date changed from 20 Dec 2019 to 20 May 2020.
13 Jul 2019 Planned number of patients changed from 120 to 250.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com